Cyclerion Therapeutics (CYCN) director Lovell received 10,000 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Stephanie Lovell (director at Cyclerion Therapeutics Inc., CYCN) reported that they received 10,000 Stock Option (Right to Buy) on Jun 24, 2021.
- Reporting person
- Lovell Stephanie
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 24, 2021 | Grant or award (A) | Stock Option (Right to Buy)On 10,000 Common Stock1 | +10,000 | - | - | 10,000 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 10,000 direct
Footnotes from the filing
- 1. The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Lovell report in this CYCN Form 4?
Stephanie Lovell (director at Cyclerion Therapeutics Inc., CYCN) reported that they received 10,000 Stock Option (Right to Buy) on Jun 24, 2021.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for CYCN
Earlier insider filings at CYCN
- Jun 28, 2021SEC Form 4 filed by Fanucci Marsha
- Jun 28, 2021SEC Form 4 filed by Isacson Ole
- Jun 28, 2021SEC Form 4 filed by Churchwell Kevin
- Jun 28, 2021SEC Form 4 filed by Mendelsohn Michael
- Jun 28, 2021SEC Form 4 filed by CONRADES GEORGE H
Quantisnow market dataNASDAQ
CYCN
Cyclerion Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for CYCN
Full CYCN profile on Quantisnow Follow CYCN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time